Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.

Clin Pharmacol Drug Dev · 2021 · PMC8451859 · PMID 33750027

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

With CYP3A4 inhibition alone, there was a slight trend for underprediction; therefore, to ensure that the worst‐case scenario was predicted, a UGT1A1 Ki value for ketoconazole was derived from the literature and included in the model.

also in 3,746 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.